However, it can be seen from the data that the HDL-C level and LDL-C level of the high-dose ACP group are closer to the normal group, indicating that the activity of ACP alleviates the lipid metabolism disorder of diabetic mice increases with an increase in dose. This evidence concerns the gene NDUFAB1 and Disorder of lipid metabolism.